Hoffmann Emily, Krähling Hermann, Kleinevoss Moritz, Bùi Công Duy, Maksoud Ziad, Holling Markus, Köhler Michael, Faizy Tobias D, Stracke Christian Paul, Akkurt Burak Han
Clinic of Radiology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Clinic of Radiology, Division of Interventional Neuroradiology, University of Münster, Münster, Germany.
Neurol Ther. 2025 Aug 22. doi: 10.1007/s40120-025-00813-y.
Perimesencephalic subarachnoid hemorrhage (pmSAH) is a rare, typically benign subtype of non-aneurysmal subarachnoid hemorrhage (SAH). While the majority of patients demonstrate a positive recovery trajectory, a subset of patients experiences complications, including vasospasm, hydrocephalus, or delayed cerebral ischemia (DCI). Reliable imaging markers for risk stratification are lacking. This study evaluates whether volumetric CT-based biomarkers-validated in aneurysmal SAH (aSAH)-are also predictive for pmSAH.
In this retrospective single-center study, 72 patients with confirmed pmSAH between 2011 and 2024 were analyzed. The automated volumetric segmentation was performed using 3D Slicer and TotalSegmentator to quantify intracranial volume (ICV), brain volume (BV), cerebrospinal fluid (CSF), and selective sulcal volume (SSV). The associations between volumetric parameters and clinical presentation, complications, and functional outcome (Glasgow Outcome Scale, GOS) were assessed using non-parametric statistics and Spearman correlation.
The median intracranial volume was 1352.7 mL, brain volume 1247.3 mL, cerebrospinal fluid volume 95.9 mL, and selective sulcal volume 19.4 mL. Vomiting at presentation was associated with higher CSF and SSV values (p = 0.04 and p = 0.005, respectively), but no significant volumetric differences were found regarding other symptoms or complications (vasospasm, hydrocephalus, DCI). GOS scores were uniformly high (median = 5), and none of the volumetric markers significantly correlated with outcome or complication rate (all p > 0.05).
In contrast to aSAH, volumetric CT biomarkers such as ICV, BV, CSF, and SSV do not offer predictive value in patients with pmSAH. Risk stratification should continue to rely on initial hemorrhage pattern and volume, clinical monitoring, and individualized assessment rather than other volumetric parameters.
中脑周围蛛网膜下腔出血(pmSAH)是一种罕见的、通常为良性的非动脉瘤性蛛网膜下腔出血(SAH)亚型。虽然大多数患者呈现出积极的恢复轨迹,但一部分患者会出现并发症,包括血管痉挛、脑积水或迟发性脑缺血(DCI)。目前缺乏用于风险分层的可靠影像学标志物。本研究评估在动脉瘤性SAH(aSAH)中得到验证的基于容积CT的生物标志物是否也能预测pmSAH。
在这项回顾性单中心研究中,分析了2011年至2024年间72例确诊为pmSAH的患者。使用3D Slicer和TotalSegmentator进行自动容积分割,以量化颅内体积(ICV)、脑体积(BV)、脑脊液(CSF)和选择性脑沟体积(SSV)。使用非参数统计和Spearman相关性评估容积参数与临床表现、并发症及功能结局(格拉斯哥结局量表,GOS)之间的关联。
颅内体积中位数为1352.7 mL,脑体积为1247.3 mL,脑脊液体积为95.9 mL,选择性脑沟体积为19.4 mL。就诊时呕吐与较高的CSF和SSV值相关(分别为p = 0.04和p = 0.005),但在其他症状或并发症(血管痉挛、脑积水、DCI)方面未发现显著的容积差异。GOS评分普遍较高(中位数 = 5),且没有容积标志物与结局或并发症发生率显著相关(所有p > 0.05)。
与aSAH不同,ICV、BV、CSF和SSV等容积CT生物标志物在pmSAH患者中没有预测价值。风险分层应继续依赖于初始出血模式和出血量、临床监测及个体化评估,而非其他容积参数。